頭頸部腫瘍における癌胎児性抗原(CEA)

概要

論文の詳細を見る
The level of carcinoembryonic antigen (CEA) in the plasma was measured by the CEA assay system established by Hansen et al. in 91 patients, consisting of 73 patients with head and neck carcinomas, 7 with malignant lymphomas, 3 with Wegeners granulomatosis, and 8 with head and neck benign tumors. The plasma CEA level higher than 5.0 ng/ml was estimated positive and 15 of 28 (53%) laryngeal carcinoma patients, 8 of 13 (62%) maxillary carcinoma patients, and one of 8 (12%) nasopharyngeal carcinoma patients were positive. In total, 34 of 73 (47%) head and neck carcinoma patients had an abnormally elevated CEA level, whereas only one of 7 (14%) malignant lymphoma patients, and none of 8 patients who had benign tumors had positive CEA level. There was no significant difference in the plasma CEA level between the patients with adenocarcinoma and those with squamous cell carcinomas. The patients of the advanced stage who had metastasis of the cervical lymphonodi and/or the other organs showed significantly higher CEA level than those of the earlier stage. It was also found that the CEA titer dropped after successful therapies, but elevated again with the reccurrence of tumors. It seems that repeated CEA determination is a valuable means for assessment of the effect of the therapies and necessary in follow-up to tumors.
社団法人日本耳鼻咽喉科学会の論文